Advances in disease biology: Therapeutic implications
- 1 April 2001
- journal article
- Published by Elsevier in Seminars in Hematology
- Vol. 38, 6-10
- https://doi.org/10.1016/s0037-1963(01)90088-5
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapyBlood, 2000
- SHP2 Mediates the Protective Effect of Interleukin-6 against Dexamethasone-induced Apoptosis in Multiple Myeloma CellsJournal of Biological Chemistry, 2000
- RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cellsOncogene, 1999
- Thalidomide — A Revival StoryNew England Journal of Medicine, 1999
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- The Telomerase Catalytic Subunit Is a Widely Expressed Tumor-Associated Antigen Recognized by Cytotoxic T LymphocytesImmunity, 1999
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.Journal of Clinical Oncology, 1998
- Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanismOncogene, 1997
- Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials.Journal of Clinical Oncology, 1992